Neoadjuvant chemotherapy provides an opportunity to assess tumor response to targeted therapies in vivo, and imaging plays a critical role in assessing the effectiveness of such therapies.

Currently no clinical standard exists for evaluating response to neoadjuvant chemotherapy, although positron emission tomography (PET) and contrast enhanced magnetic resonance imaging (MRI) are promising candidate technologies.

Positron emission tomography with fluorodeoxyglucose provides information about tumor metabolism that can powerfully predict treatment response early in the course of therapy, before anatomic changes become evident on MRI scans.

The recent development of a high-resolution, breast specific PET imaging system allows more detailed characterization of the primary breast tumor than conventional whole body PET systems.

We report on the usage of dedicated breast PET to provide early assessment of treatment response in a patient with bilateral synchronous breast cancers.

‍